Terumo Announces All Dexcom G6 CGM System Users on Insulin Therapy to be Covered by Insurance in Japan

December 1, 2022

Corporate

TOKYO, JAPAN – December 1, 2022 – Terumo Corporation today announced that all users of the Dexcom G6 Continuous Glucose Monitoring (CGM) System on insulin therapy in Japan will now be covered by insurance, expanding patient access to this glucose monitoring technology.

This expanded insurance coverage removes a significant cost barrier for patients on insulin therapy who could benefit from continuous glucose monitoring, supporting better diabetes management through real-time glucose data.

"This expanded coverage is an important step in improving access to continuous glucose monitoring technology for patients with diabetes in Japan," said a Terumo representative. "We are committed to helping ensure that more patients on insulin therapy can benefit from this important tool for diabetes management."

The Dexcom G6 System provides real-time glucose readings, helping patients and their healthcare providers make more informed treatment decisions and potentially improving overall diabetes management outcomes.

About Terumo India

Terumo India is a fast-growing medical devices company that serves to advance access to high-quality Cardiac & Vascular, and other medical devices for patients and medical practitioners in India. Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. Established in 1921 and with its 100 years of history, Terumo's starting point and unchanging corporate mission has been 'Contributing to Society through Healthcare'.

Terumo India was established in 2013 with headquarters in Gurgaon, NCR Delhi and has since grown to touch over 100,000 lives with an expanding field force & distribution network. Terumo India is Great Place to Work® certified and has also been recognized as one of India's Top 15 Workplaces™ in Pharmaceuticals, Healthcare and Biotech 2022. The company runs several acclaimed training & development programs, working closely with its customers and academic partners to contribute to the skilling requirements of India's healthcare system.

Media Contact

Terumo India Private Limited

About Terumo

Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of "Contributing to Society through Healthcare." Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.

Media Contact

Corporate Communication Dept., Terumo Corporation

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.